These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 21381966

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
    Lee CH, Su TY, Ye JJ, Hsu PC, Kuo AJ, Chia JH, Lee MH.
    J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
    [Abstract] [Full Text] [Related]

  • 4. Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes.
    Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO.
    Infect Control Hosp Epidemiol; 2006 Sep; 27(9):893-900. PubMed ID: 16941312
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years].
    Nasu Y, Abe M, Ono N, Araki M, Horimi T, Takahashi I.
    Jpn J Antibiot; 2004 Oct; 57(5):438-48. PubMed ID: 15655905
    [Abstract] [Full Text] [Related]

  • 8. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
    Sader HS, Huband MD, Castanheira M, Flamm RK.
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes.
    Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M.
    Infect Control Hosp Epidemiol; 2010 Jan; 31(1):47-53. PubMed ID: 19951202
    [Abstract] [Full Text] [Related]

  • 11. Imipenem-resistant Pseudomonas aeruginosa: risk factors for nosocomial infections.
    Onguru P, Erbay A, Bodur H, Baran G, Akinci E, Balaban N, Cevik MA.
    J Korean Med Sci; 2008 Dec; 23(6):982-7. PubMed ID: 19119440
    [Abstract] [Full Text] [Related]

  • 12. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
    López-Dupla M, Martínez JA, Vidal F, Almela M, Soriano A, Marco F, López J, Olona M, Mensa J.
    Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
    [Abstract] [Full Text] [Related]

  • 13. [Evolution of antimicrobial resistance against Pseudomonas aeruginosa in a French university hospital between 2002 and 2006].
    Minchella A, Molinari L, Alonso S, Bouziges N, Sotto A, Lavigne JP.
    Pathol Biol (Paris); 2010 Feb; 58(1):1-6. PubMed ID: 19875241
    [Abstract] [Full Text] [Related]

  • 14. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
    Master RN, Clark RB, Karlowsky JA, Ramirez J, Bordon JM.
    Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Systemic inflammatory response syndrome in adult patients with nosocomial bloodstream infection due to Pseudomonas aeruginosa.
    Marra AR, Bar K, Bearman GM, Wenzel RP, Edmond MB.
    J Infect; 2006 Jul; 53(1):30-5. PubMed ID: 16253333
    [Abstract] [Full Text] [Related]

  • 17. Bacteremia due to Pseudomonas aeruginosa: results from a 3-year national study in the Slovak Republic.
    Koprnova J, Beno P, Korcova J, Mrazova M, Grey E, Liskova A, Harnicarova A, Karvaj M, Koval S, Zak V, Danaj M, Streharova A, Mitterpachova E, Miklosko J, Ondrusova A, Riedl J, Kaiserova E, Prokopova V, Hornova M, Payer J, Rudinsky B, Pevalova L, Bencelova M, Hanzen J, Macekova L, Csölleyova J, Krcmery V.
    J Chemother; 2005 Oct; 17(5):470-6. PubMed ID: 16323434
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
    Tam VH, Gamez EA, Weston JS, Gerard LN, Larocco MT, Caeiro JP, Gentry LO, Garey KW.
    Clin Infect Dis; 2008 Mar 15; 46(6):862-7. PubMed ID: 18279040
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.